AMLN - comments?

[jiesen]

Hmm, yeah, I'd love to watch that, but unfortunately I'm stuck at work. Thanks for pointing that out though! Must be going on right about now, eh?

[billyjoe]

Jiesen,
CNBC is going to have what they call a very interesting interview with AMLN's CEO today perhaps at noon est thought you might be interested.

billyjoe

[jiesen]

AMLN replaces MCI in Nasdaq-100 index

http://biz.yahoo.com/prnews/060106/dcf028.html?.v=29

[jiesen]

I should have taken the entry signal 2 days ago on AMLN. Jiesen you've had this one for while if I recall.

Awesome job Your HUGE!!!

Thanks, Runner! Yeah, I first bought it around $21 and unfortunately sold half at $27, thinking it had spiked AH and would be coming back down the next day, for me to pick back up. Didn't happen, though. I'm not letting any more go until it's MUCH higher than this.

I should have taken the entry signal 2 days ago on AMLN. Jiesen you've had this one for while if I recall.

Awesome job Your HUGE!!!

[jiesen]

Lye,

you're in very good company with your purchase today:

http://investors.amylin.com/phoenix....ZhdHRhY2g9b24=


Joe Cook used to run the show at AMLN. A vote of confidence from him is HUGE.

[Lyehopper]

HUUUUUUUUGE!!!!! Hehehehehehehe!

Jiesen you've got the POTW this week dude!

[jiesen]

I got me some Jiesen @ 40.50

might be breaking out for real now.

Cool. We'll be riding this AMLN bull together then!

[Lyehopper]

I got me some Jiesen @ 40.50

might be breaking out for real now.

[jiesen]

I'm just throwing that out there in response to your concern about AMLN's competition- but I should qualify this by saying I'm really not an expert, and can't pretend that I really have all the facts straight here. So please, if you know more about this, feel free to correct me where I'm wrong. I'm sorry if it seems like I'm pumping AMLN, but I am excited about owning this stock, and am just rambling off my own reasons for feeling this way- not claiming that I know everything about it- my understanding of the diabetes drug market, or of AMLN for that matter, could turn out to be 100% wrong... so take this all with a grain of salt, please! thought I should add a disclaimer that I'm coming off of a slight buzz tonight, too.

more info...
how Byetta works:

http://www.byetta.com/hcp/200_incretin_mimetic.jsp?reqNavId=2

how Byetta and Symlin are selling:

http://members.cox.net/mystock/Amylin.htm

note- $20M last quarter, heading for $50-60M this quarter. Should see a $1B+ year in the not too distant future.

[jiesen]

You mean GLP-1 agonists, right? No, I'd not be worried about competition in this area, because Byetta actually IS a GLP-1 agonist, and the first to market at that. If another were to come to market, it would have to be demonstrated to be more effective than Byetta, and there really isn't anything close to that right now. These things take years (or decades sometimes) to get through all the clinical and regulatory hoops to make it on the market. AMLN is practically one of a kind in that they made it with a novel diabetes treatment (two, actually!). Competition could be considered stiff coming from SNY/PFE's Exubera, but that's still insulin, which is an inferior treatment to a GLP-1 agonist. Novartis has an interesting candidate that may compete, eventually, in a DPPIV inhibitor, which works like a GLP-1 agonist, but again that's still a ways off (2008 at the earliest) but it would still have to prove to be better than Byetta if it's going to really steal market share from them. The only thing it has going over Byetta is that it's an oral rather than injectible. But that difference is highly overrated by the investment community. By the time they make it to maket, AMLN will probably have LARS on the market, and have sold enough Byetta to buy whatever else is new in the diabetes arena. They are working on new business deals even now that will solidify their pipeline and their position as a leader in the market for years to come. Byetta is huge, but it is just the beginning for AMLN. Also, you can't buy another successful diabetes drug company like AMLN, the rest (PFE, LLY, SNY, NVS etc) all have the big pharma baggage that comes with it.

Amln

Looks like AMLN has finally made it over $40. Awesome!!!
I am slightly concerned about the GLIP antagonists in the clinic as possible competitors.
What is your opinion Jaisen?

Thanks
JMS

[spikefader]

watch out! AMLN is sneaking up on 40!

Dude! I'm still hugely bullish on it. And it's got those delicious scallops bullish pattern.



A qualdruple top breakout; shoot, this one is worth some calls!

[jiesen]

Sheesh, that really is a wicked double top on the weekly. But it IS coming off a c long on the weekly. jiesen, even you can see the 12345abc move right?? hehe

I see 37.58 gap fill resisting strongly, and then channel resistance at 38.35ish. If I were long, there is absolutely no question I'd be selling it there and wait. In fact, I'd be tempted to buy puts or short there. NB may even say he'd sell calls. NB? Would ya??

BUT: If it breaks out over that double top, woohoo! It's going to 50 pretty quickly.

watch out! AMLN is sneaking up on 40!

[spikefader]

Sheesh, that really is a wicked double top on the weekly. But it IS coming off a c long on the weekly. jiesen, even you can see the 12345abc move right?? hehe

I see 37.58 gap fill resisting strongly, and then channel resistance at 38.35ish. If I were long, there is absolutely no question I'd be selling it there and wait. In fact, I'd be tempted to buy puts or short there. NB may even say he'd sell calls. NB? Would ya??

BUT: If it breaks out over that double top, woohoo! It's going to 50 pretty quickly.